Ignite Creation Date:
2025-12-26 @ 11:09 AM
Ignite Modification Date:
2026-01-13 @ 11:00 PM
Study NCT ID:
NCT00073112
Status:
COMPLETED
Last Update Posted:
2007-11-29
First Post:
2003-11-17
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Study of ABT-751 in Patients With Renal Cell Cancer
Sponsor:
Abbott
Organization:
Study Overview
Official Title:
A Phase 2 Study of ABT-751 in Subjects With Refractory Colorectal Carcinoma
Status:
COMPLETED
Status Verified Date:
2007-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of the study is to determine if ABT-751 will decrease tumors, and determine how long the tumor shrinkage can be maintained in patients with renal cell cancer. Patients will receive ABT-751 by mouth daily for 21 days. Patients will be off drug for 7 days before starting the next cycle of drug.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
NCT ID Aliases
| NCT ID Alias | NCT ID | View |
|---|---|---|
| None | NCT00073112 | View |